(Q35042575)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21687579%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

review article

1 reference

title

An overview of the clinical use of antimuscarinics in the treatment of overactive bladder (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21687579%20AND%20SRC:MED&resulttype=core&format=json

Anastasios Athanasopoulos

5 February 2020

author

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21687579%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

author name string

Konstantinos Giannitsas

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21687579%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

publication date

7 June 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21687579%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21687579%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

volume

2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21687579%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

page(s)

820816

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21687579%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 3.0 Unported

5 February 2020

copyright license

start time

1 January 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Antimuscarinic mechanisms and the overactive detrusor: an update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114080

Patient‐optimized doses of fesoterodine improve bladder symptoms in an open‐label, flexible‐dose study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114080

Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114080

Antimuscarinics and bladder outlet obstruction: From a contraindication to an indication?

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114080

Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114080

Urinary urgency outcomes after propiverine treatment for an overactive bladder: the 'Propiverine study on overactive bladder including urgency data'.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114080

Antimuscarinics in men with lower urinary tract symptoms suggestive of bladder outlet obstruction due to benign prostatic hyperplasia

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114080

The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114080

Darifenacin for the treatment of overactive bladder

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114080

Antimuscarinics and overactive bladder: other mechanism of action

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114080

Listening to the patient: a flexible approach to the use of antimuscarinic agents in overactive bladder syndrome

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114080

Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114080

Muscarinic receptor subtypes in the lower urinary tract

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114080

Muscarinic receptor antagonists for overactive bladder treatment: does one fit all?

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114080

Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114080

Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114080

Long-term benefits of darifenacin treatment for patient quality of life: results from a 2-year extension study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114080

A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114080

The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114080

Tolterodine for the treatment of overactive bladder

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114080

Overactive bladder: an update.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114080

Solifenacin succinate for the treatment of symptoms of overactive bladder

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114080

The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114080

Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: A systematic review

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114080

Efficacy of the combination of an alpha1-blocker with an anticholinergic agent in the treatment of lower urinary tract symptoms associated with bladder outlet obstruction

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114080

Persistence with antimuscarinic therapy in patients with overactive bladder

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114080

Propiverine versus tolterodine: efficacy and tolerability in patients with overactive bladder.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114080

The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114080

Darifenacin: a novel M3 muscarinic selective receptor antagonist for the treatment of overactive bladder

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114080

Trospium chloride in the management of overactive bladder

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114080

The emerging role of solifenacin in the treatment of overactive bladder

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114080

Oxybutynin extended-release: a review of its use in the management of overactive bladder

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114080

Transdermal oxybutynin: a new treatment for overactive bladder

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114080

Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114080

Trospium chloride--an effective drug in the treatment of overactive bladder and detrusor hyperreflexia

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114080

Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic).

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114080

Oxybutynin and the overactive bladder

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114080

8 July 2018

Tolterodine: an overview

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114080

Tolterodine--a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114080

Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114080

Intravesical oxybutynin: a local anesthetic effect on bladder C afferents

8 July 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F820816

Formulation study of intravesical oxybutynin instillation solution with enhanced retention in bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F820816

Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F820816

Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F820816

Impact of transdermal oxybutynin on work productivity in patients with overactive bladder: results from the MATRIX study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F820816

Comparison of the efficacy of tolterodine and oxybutynin in different urodynamic severity grades of idiopathic detrusor overactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F820816

A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F820816

Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F820816

A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F820816

Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F820816

Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F820816

Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F820816

Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head‐to‐head, placebo‐controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F820816

Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F820816

Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F820816

Assessment of cognitive function of the elderly population: effects of darifenacin

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F820816

Trospium chloride is undetectable in the older human central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F820816

Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants > or = 50 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F820816

QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F820816

A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F820816

Cardiovascular safety and overall tolerability of solifenacin in routine clinical use: a 12-week, open-label, post-marketing surveillance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F820816

Overactive bladder medication adherence when medication is free to patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F820816

Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F820816

A prospective observational study of the effects of treatment with extended-release tolterodine on health-related quality of life of patients suffering overactive bladder syndrome in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F820816

Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F820816

Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2011%2F820816

Thorough QT study of the effect of fesoterodine on cardiac repolarization

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114080

Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study.

25 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3114080

Patient-reported reasons for discontinuing overactive bladder medication

25 October 2018

1 reference

12 December 2020

Safety of anticholinergics in patients with benign prostatic hyperplasia

1 reference

12 December 2020

Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder

1 reference

12 December 2020

Treatment Outcomes in the STAR Study: A Subanalysis of Solifenacin 5 mg and Tolterodine ER 4 mg

1 reference

12 December 2020

Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome

1 reference

12 December 2020

Effect of oxybutynin on the QTc interval in elderly patients with urinary incontinence

1 reference

12 December 2020

Cost Effectiveness of Controlled-Release Oxybutynin Compared with Immediate-Release Oxybutynin and Tolterodine in the Treatment of Overactive Bladder in the UK, France and Austria

1 reference

12 December 2020

Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity

1 reference

12 December 2020

Clinical Efficacy, Safety, and Tolerability of Once-Daily Fesoterodine in Subjects with Overactive Bladder

1 reference

12 December 2020

Thorough QT study with recommended and supratherapeutic doses of tolterodine

1 reference

12 December 2020

Identifiers

DOI

10.1155/2011/820816

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21687579%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21687579%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

PubMed publication ID

21687579

1 reference